2.Peripartum acute anterior ST segment elevation myocardial infarction: an uncommon presentation of acute aortic dissection.
Abdul Razakjr OMAR ; Wei-Ping GOH ; Yean-Teng LIM
Annals of the Academy of Medicine, Singapore 2007;36(10):854-856
INTRODUCTIONAtherosclerotic coronary artery thrombosis is the most common cause of acute myocardial infarction.
CLINICAL PICTUREA 30-year-old lady presented with acute peripartum massive anterior ST segment myocardial infarction and cardiogenic shock. This was due to acute Stanford type A aortic dissection with the intimal flap occluding the left coronary ostium. The initial diagnosis was not apparent. Echocardiography confirmed the diagnosis.
TREATMENT AND OUTCOMEShe underwent emergency surgical repair (Bentall procedure). Pathology confirmed underlying idiopathic cystic medial degeneration.
CONCLUSIONA high index of clinical suspicion is required in acute myocardial infarction presenting without traditional cardiovascular risk factors.
Acute Disease ; Adult ; Aneurysm, Dissecting ; complications ; diagnosis ; surgery ; Aortic Aneurysm ; complications ; diagnosis ; surgery ; Echocardiography ; Electrocardiography ; Female ; Humans ; Myocardial Infarction ; etiology ; physiopathology ; Pregnancy ; Pregnancy Complications, Cardiovascular ; Shock, Cardiogenic ; etiology
4.First transcatheter aortic valve implantation for severe pure aortic regurgitation in Asia.
Paul Toon-Lim CHIAM ; See Hooi EWE ; Yeow Leng CHUA ; Yean Teng LIM
Singapore medical journal 2014;55(2):103-105
Transcatheter aortic valve implantation (TAVI) has become the standard of care for inoperable patients with symptomatic severe aortic stenosis (AS), and an alternative to open aortic valve replacement for patients at high surgical risk. TAVI has also been performed in several groups of patients with off-label indications such as severe bicuspid AS, and as a valve-in-valve therapy for a degenerated surgical bioprosthesis. Although TAVI with CoreValve® prosthesis is technically challenging, and global experience in the procedure is limited, the procedure could be a treatment option for well-selected patients with severe pure aortic regurgitation (AR). Herein, we report Asia's first case of TAVI for severe pure AR in a patient who was at extreme surgical risk, with good clinical outcome at six months.
Adult
;
Aortic Valve
;
surgery
;
Aortic Valve Insufficiency
;
surgery
;
Aortic Valve Stenosis
;
surgery
;
Asia
;
Echocardiography
;
Endocarditis
;
complications
;
therapy
;
Fluoroscopy
;
Heart Valve Prosthesis
;
Hemodynamics
;
Humans
;
Male
;
Prosthesis Design
;
Prosthesis Implantation
;
methods
;
Treatment Outcome
5.Framingham risk score inadequately predicts cardiac risk in young patients presenting with a first myocardial infarction.
Glenn K M LEE ; Li-Ching LEE ; Christopher W Y LIU ; Shir Lynn LIM ; Lu-Ming SHI ; Hean-Yee ONG ; Yean-Teng LIM ; Tiong-Cheng YEO
Annals of the Academy of Medicine, Singapore 2010;39(3):163-167
INTRODUCTIONThe Framingham Risk Score (FRS) is a well-validated epidemiologic tool used to assess the risk for a fi rst cardiac event. Because young patients presenting with a fi rst myocardial infarction (MI) tend to have less significant risk profiles compared with older patients, we hypothesized that FRS may underestimate cardiac risk in these patients.
MATERIALS AND METHODSWe studied 1267 patients between January 2002 and November 2007 presenting with a fi rst MI. Patients with pre-existing diabetes mellitus and vascular disease were excluded. FRS was calculated for each patient. Patients were divided based on their age: group A (<40 years), group B (40 to 64 years) and group C (> or =65 years).
RESULTSThe mean age was 54.7 +/- 11 years, 88.4% of the patients were males. Younger patients were more likely to be assigned with lower scores. Based on FRS, 63.0%, 29.3% and 14.2% of group A, B and C patients were classified as low risk (10-year risk for cardiac events<10%) respectively, P <0.001. The sensitivity of FRS in identifying at least intermediate risk subjects (10-year risk for cardiac events >10%) was 37.0% in group A vs 85.8% in group C (P <0.001). The incidence of newly diagnosed diabetes mellitus was higher in younger patients (12.0% vs 13.2% vs 7.1 % in groups A, B and C respectively, P = 0.027).
CONCLUSIONSFRS inadequately predicts cardiac risk in young patients presenting with a fi rst MI. This could be because a significant proportion of these young patients have undiagnosed diabetes mellitus, a coronary artery disease risk equivalent.
Adult ; Age Factors ; Aged ; Algorithms ; Diabetes Complications ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction ; complications ; diagnosis ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Sex Factors
6.Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.
Jonathan YAP ; Mun Yee THAM ; Jalene POH ; Dorothy TOH ; Cheng Leng CHAN ; Toon Wei LIM ; Shir Lynn LIM ; Yew Woon CHIA ; Yean Teng LIM ; Jonathan CHOO ; Zee Pin DING ; Ling Li FOO ; Simin KUO ; Yee How LAU ; Annie LEE ; Khung Keong YEO
Annals of the Academy of Medicine, Singapore 2022;51(2):96-100
INTRODUCTION:
Despite reports suggesting an association between COVID-19 mRNA vaccination and pericarditis and myocarditis, detailed nationwide population-based data are sparsely available. We describe the incidence of pericarditis and myocarditis by age categories and sex after COVID-19 mRNA vaccination from a nationwide mass vaccination programme in Singapore.
METHODS:
The incidence of adjudicated cases of pericarditis and myocarditis following COVID-19 mRNA vaccination that were reported to the vaccine safety committee between January to July 2021 was compared with the background incidence of myocarditis in Singapore.
RESULTS:
As of end July 2021, a total of 34 cases were reported (9 pericarditis only, 14 myocarditis only, and 11 concomitant pericarditis and myocarditis) with 7,183,889 doses of COVID-19 mRNA vaccine administered. Of the 9 cases of pericarditis only, all were male except one. The highest incidence of pericarditis was in males aged 12-19 years with an incidence of 1.11 cases per 100,000 doses. Of the 25 cases of myocarditis, 80% (20 cases) were male and the median age was 23 years (range 12-55 years) with 16 cases after the second dose. A higher-than-expected number of cases were seen in males aged 12-19 and 20-29 years, with incidence rates of 3.72 and 0.98 case per 100,000 doses, respectively.
CONCLUSION
Data from the national registry in Singapore indicate an increased incidence of pericarditis and myocarditis in younger men after COVID-19 mRNA vaccination.
Adolescent
;
Adult
;
COVID-19/prevention & control*
;
COVID-19 Vaccines/adverse effects*
;
Child
;
Female
;
Humans
;
Male
;
Middle Aged
;
Myocarditis/etiology*
;
Pericarditis/etiology*
;
RNA, Messenger
;
SARS-CoV-2
;
Vaccination/adverse effects*
;
Vaccines, Synthetic
;
Young Adult
;
mRNA Vaccines